A client with highly specialised therapies for serious & life-threatening diseases engaged HTAnalysts.

The challenge

Negotiate a complex risk-share agreement that required:
Building a mutually acceptable pricing mechanism. Liaising with clients stakeholders (local affiliate, global HEOR & pricing, medical and corporate teams), and the Government Stakeholders, including the DoH, PBAC and the Minister. Facilitating and reaching agreement with all stakeholders.

Actions:

• Application

  Application to the PBAC completed by HTAnalysts.

• Cost effectiveness

  Argument strengthened with respect to survival gain, dose adjustments and utility benefits.

• Additional local evidence

  Obtained (ultimately used internationally). Innovative performance-based pricing strategy developed replacing ‘usual practice’ of initiation and continuation rules.

• Internal financial modelling

  Developed by HTAnalysts taking into account various performance outcomes and pricing scenarios.

• Evidence

  HTAnalysts negotiated final complex risk-sharing arrangement with appropriate post-listing evidence collection.

Result

Successful reimbursement with ongoing access for all eligible patients, achieved in faster time than comparable highly-specialised products.

Download case study